Transforming Cancer Research: AWS and D3b’s RADIANT Collaboration Puts Data and AI to Work for Kids
Every day, families receive the unthinkable news of a childhood cancer diagnosis, and a powerful alliance between the Children’s Hospital of Philadelphia’s Center for Data-Driven Discovery in Biomedicine (D3b) and Amazon Web Services (AWS) is delivering more than just hope. D3b recognizes that the key to unlocking new, life-saving treatments lies in breaking down the data silos that have long hampered progress. This vital partnership is dismantling these barriers with a revolutionary pediatric research model: the Real-time Analysis and Discovery in Integrated and Networked Technologies (RADIANT) project.
The Children’s Brain Tumor Network (CBTN), a D3b program, created a groundbreaking framework for sharing complex molecular, imaging, and clinical data across 35 leading pediatric research institutions worldwide. Dr. Rowland Illing, AWS’ Global Chief Medical Officer, states that “Data is the pediatric cancer and rare disease community’s superpower. Powered by AWS’ secure, scalable cloud infrastructure, RADIANT is the type of unprecedented near real-time data sharing mechanism that can get the right insights into the right patients, clinicians, and researchers when every second counts.”
Building upon that success, funding through the Agency for Research Projects in Health (ARPA-H), National Institutes of Health (NIH), and generous assistance from AWS have connected front-line clinicians and laboratory researchers. The goal: to leverage advanced artificial intelligence (AI) systems to more rapidly identify personalized treatment options for young patients fighting aggressive cancers and rare diseases.
RADIANT emerged as a direct result of this shared vision to accelerate discovery, enabling pediatric oncologists to instantly share critical patient insights with research scientists and other specialized care teams across institutional boundaries. It sets a new standard for precision medicine, directly benefiting children with medulloblastoma, diffuse intrinsic pontine glioma (DIPG), neuroblastoma, and other devastating pediatric conditions. For families facing these diagnoses, this means faster access to targeted therapies, reduced treatment toxicity, and ultimately, improved survival rates and quality of life.
The critical collaboration between D3b and AWS powers RADIANT to transform pediatric cancer research, turning valuable data into a tangible source of hope for children and families facing life’s most difficult challenges.
To learn more about this partnership and how AWS and D3b are driving discoveries faster than ever before, please visit here.